Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Chemotherapy|DRUG: Genomic driven chemotherapy
Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Collaborators: Institut Curie